RJA
BMRN icon

Ross\Johnson & Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ross\Johnson & Associates’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57 Buy
+1
New +$55 ﹤0.01% 333

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ross\Johnson & Associates's BMRN Position: Q2 2026 in Review

Ross\Johnson & Associates opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 1 share worth $57. The stake represents ﹤0.01% of the portfolio and ranks #333 among its holdings.

561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Ross\Johnson & Associates held 1 share of BioMarin Pharmaceuticals worth $57 as of Q2 2026.
  • BioMarin Pharmaceuticals was a new Ross\Johnson & Associates position in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Ross\Johnson & Associates's portfolio in Q2 2026, its #333 holding.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Ross\Johnson & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.